Nijmegen, Netherlands

Ryan Heesbeen

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 56(Granted Patents)


Location History:

  • CM Nijmegen, NL (2022)
  • Nijmegen, NL (2018 - 2024)

Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations by Inventor Ryan Heesbeen in Nijmegen, NL

Introduction

Ryan Heesbeen, a prominent inventor based in Nijmegen, NL, has made significant contributions to the field of bioconjugates, with a total of six patents to his name. His innovative work focuses on enhancing the efficacy and stability of therapeutic agents, particularly in the development of antibody-drug conjugates.

Latest Patents

Among his most recent inventions, Ryan has developed "Sulfamide linkers for use in bioconjugates," which presents a novel linker design aimed at improving conjugation efficiency. This invention addresses essential aspects such as reducing aggregation and increasing the therapeutic index of bioconjugates. Another notable patent is for "Antibody-conjugates with improved therapeutic index for targeting CD30 tumours." This innovation introduces a specific mode of conjugation that enhances the performance of antibody-conjugates by using a glycoprotein with particular properties, ultimately improving their ability to target CD30-expressing cells.

Career Highlights

Ryan Heesbeen’s career is marked by his association with Synaffix B.V., where he lends his expertise to ongoing research and development in bioconjugate technology. His inventive spirit and commitment to excellence have positioned him as a key figure within the company, leading efforts to push the boundaries of pharmaceutical innovation.

Collaborations

Throughout his career, Ryan has collaborated with distinguished colleagues such as Floris Louis Van Delft and Maria Antonia Wijdeven. Together, they contribute to the advancement of bioconjugate strategies, leveraging their combined knowledge and experience to create effective therapeutic solutions.

Conclusion

In conclusion, Ryan Heesbeen exemplifies the spirit of innovation within the field of bioconjugates. His latest patents demonstrate significant advancements in the development of therapeutic agents, benefiting both the medical community and patients. As he continues his work at Synaffix B.V., Ryan’s contributions are sure to shape the future of targeted therapies and improve treatment outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…